Lineage Cell Therapeutics, Inc. (LCTX) — SEC Filings
Lineage Cell Therapeutics, Inc. (LCTX) — 34 SEC filings. Latest: DEFA14A (Apr 29, 2026). Includes 16 8-K, 6 10-Q, 3 DEF 14A.
View Lineage Cell Therapeutics, Inc. on SEC EDGAR
Overview
Lineage Cell Therapeutics, Inc. (LCTX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEFA14A filed on Apr 29, 2026: Lineage Cell Therapeutics, Inc. filed a DEFA14A on April 29, 2026, related to additional definitive proxy soliciting materials. The filing includes proxy materials and graphic elements, with the company's principal executive offices located at 2173 Salk Avenue, Suite 200, Carlsbad, CA 92008.
Sentiment Summary
Across 34 filings, the sentiment breakdown is: 1 bullish, 3 bearish, 30 neutral. The dominant filing sentiment for Lineage Cell Therapeutics, Inc. is neutral.
Filing Type Overview
Lineage Cell Therapeutics, Inc. (LCTX) has filed 2 DEFA14A, 1 EFFECT, 16 8-K, 6 10-Q, 3 DEF 14A, 2 10-K, 2 SC 13D/A, 2 SC 13G with the SEC between Feb 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (34)
Risk Profile
Risk Assessment: Of LCTX's 28 recent filings, 2 were flagged as high-risk, 10 as medium-risk, and 16 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $7.948M |
| Net Income | -$64.259M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $40.463M |
| Operating Margin | N/A |
| Total Assets | $89.639M |
| Total Debt | N/A |
Key Executives
- Neal C. Bradsher
- Neal Bradsher
Industry Context
Lineage Cell Therapeutics operates in the biotechnology sector, focusing on developing cell therapies for unmet medical needs. This industry is characterized by high research and development costs, long development timelines, significant regulatory hurdles, and intense competition from both established pharmaceutical companies and emerging biotech firms. Success often hinges on clinical trial outcomes and the ability to secure substantial funding for ongoing development and commercialization.
Top Tags
Biotechnology (4) · sec-filing (4) · 10-Q (4) · biotech (4) · 8-K (3) · regulatory-filing (3) · financials (3) · biotechnology (3) · financing (3) · Cell Therapy (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Commission File Number | 001-12830 | Identifies the company's SEC filing history |
| IRS Employer Identification No. | 94-3127919 | Company's tax identification number |
| Net Loss | $64.259M | Increased significantly from $15.332M in 2024 for the nine months ended September 30. |
| Change in Fair Value of Warrant Liability | $36.992M | Major contributor to the increased net loss for the nine months ended September 30, 2025. |
| Loss on Impairment of Intangible Asset | $14.840M | Significant non-cash operating expense for the nine months ended September 30, 2025. |
| Cash and Cash Equivalents | $40.463M | Decreased from $45.789M at December 31, 2024, indicating ongoing cash burn. |
| Total Revenues | $7.948M | Increased from $6.631M in 2024 for the nine months ended September 30. |
| Net Cash Used in Operating Activities | $14.041M | For the nine months ended September 30, 2025, reflecting operational cash burn. |
| Common Shares Outstanding (in thousands) | 230,328 | Increased from 220,416 thousand at December 31, 2024, due to financing activities. |
| Total Assets | $89.639M | Decreased from $113.218M at December 31, 2024, primarily due to intangible asset impairment. |
| Warrant Liabilities | $45.171M | Increased significantly from $6.161M at December 31, 2024, reflecting increased valuation. |
| Total Shareholders' Equity | $20.796M | Decreased substantially from $77.012M at December 31, 2024. |
| R&D Expenses | $12.5M | Increased from $11.8M in prior year period, reflecting continued investment. |
| Increase in Net Loss | 8.6% | Percentage increase in net loss from $16.2 million to $17.6 million year-over-year. |
| Fiscal Quarter End | Q1 --12-31 2025 | Indicates the period covered by the report. |
Forward-Looking Statements
- {"claim":"Broadwood Partners, L.P. will likely maintain its significant ownership stake in Lineage Cell Therapeutics, Inc. in the near term.","entity":"Broadwood Partners, L.P.","targetDate":"Q2 2024","confidence":"high"}
- {"claim":"The substantial ownership by Broadwood Partners, L.P. could provide a floor for the stock price, reducing extreme downside volatility.","entity":"Lineage Cell Therapeutics, Inc.","targetDate":"Q4 2024","confidence":"medium"}
Frequently Asked Questions
What are the latest SEC filings for Lineage Cell Therapeutics, Inc. (LCTX)?
Lineage Cell Therapeutics, Inc. has 34 recent SEC filings from Feb 2024 to Apr 2026, including 16 8-K, 6 10-Q, 3 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of LCTX filings?
Across 34 filings, the sentiment breakdown is: 1 bullish, 3 bearish, 30 neutral. The dominant sentiment is neutral.
Where can I find Lineage Cell Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Lineage Cell Therapeutics, Inc. (LCTX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Lineage Cell Therapeutics, Inc.?
Key financial highlights from Lineage Cell Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for LCTX?
The investment thesis for LCTX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Lineage Cell Therapeutics, Inc.?
Key executives identified across Lineage Cell Therapeutics, Inc.'s filings include Neal C. Bradsher, Neal Bradsher.
What are the main risk factors for Lineage Cell Therapeutics, Inc. stock?
Of LCTX's 28 assessed filings, 2 were flagged high-risk, 10 medium-risk, and 16 low-risk.
What are recent predictions and forward guidance from Lineage Cell Therapeutics, Inc.?
Recent forward-looking statements from Lineage Cell Therapeutics, Inc. include guidance on {"claim":"Broadwood Partners, L.P. will likely maintain its significant ownership stake in Lineage Cell Therapeutics, In and 1 other predictions.